Innovent expands Phase 3 lung cancer trial to non-squamous NSCLC
Tweet Send to a Friend
Innovent Biologics (HKEX: 01801) announced the expansion of its global Phase 3 MarsLight-11 clinical trial (NCT07217301) to include patients with ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
